Five Prime Therapeutics, Inc. (FPRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
FPRX Stock Price Chart Interactive Chart >
FPRX Price/Volume Stats
| Current price | $38.00 | 52-week high | $38.90 |
| Prev. close | $37.99 | 52-week low | $2.61 |
| Day low | $37.95 | Volume | 1,006,600 |
| Day high | $38.01 | Avg. volume | 1,981,352 |
| 50-day MA | $31.27 | Dividend yield | N/A |
| 200-day MA | $15.17 | Market Cap | 1.77B |
Five Prime Therapeutics, Inc. (FPRX) Company Bio
Five Prime Therapeutics discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. The company was founded in 2001 and is based in South San Francisco, California.
Latest FPRX News From Around the Web
Below are the latest news stories about Five Prime Therapeutics Inc that investors may wish to consider to help them evaluate FPRX as an investment opportunity.
Amgen Completes The Acquisition Of Five Prime TherapeuticsAmgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had previously announced a tender offer to buy all outstanding common stock at the price of $38.00 per share in cash. The aggregate payment that was to be made for the merger is $1.9B, excluding transaction expenses. Amgen is a biotech company that focuses on unlocking biological potential and innovations that cater to patients suffering from serious illnesses. Amgen (AMGN) focuses on unmet needs in the human therapeutics field, and Five Prime Therapeutics (FPRX) will add to its overall oncology portfolio. |
Amgen Successfully Completes Acquisition Of Five Prime TherapeuticsAmgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds HWCC, FI, SVBI, and FRPX Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Halper Sadeh LLP Investigates the Following Mergers - TPCO, STAY, KSU, CUB, AEGN, FPRX; Shareholders Are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: |
Lifshitz Law Firm, P.C. Announces Investigation of FPRX, NBLX, PAND, and SHBINEW YORK, NY / ACCESSWIRE / March 21, 2021 / Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Lifshitz Law Firm, P. |
FPRX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 696.65% |
| 5-year | 94.37% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 270.59% |
| 2019 | -50.65% |
| 2018 | -57.57% |
Continue Researching FPRX
Here are a few links from around the web to help you further your research on Five Prime Therapeutics Inc's stock as an investment opportunity:Five Prime Therapeutics Inc (FPRX) Stock Price | Nasdaq
Five Prime Therapeutics Inc (FPRX) Stock Quote, History and News - Yahoo Finance
Five Prime Therapeutics Inc (FPRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...